Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$22.41 - $41.99 $11.2 Million - $21 Million
500,000 New
500,000 $11.2 Million
Q4 2022

Feb 14, 2023

BUY
$33.53 - $54.79 $10.1 Million - $16.6 Million
302,135 New
302,135 $11.5 Million
Q3 2020

Nov 16, 2020

SELL
$45.41 - $57.07 $15 Million - $18.8 Million
-330,000 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$42.56 - $54.98 $61 Million - $78.8 Million
-1,433,387 Reduced 81.29%
330,000 $16.7 Million
Q1 2020

May 15, 2020

BUY
$32.37 - $59.36 $433,337 - $794,652
13,387 Added 0.76%
1,763,387 $78.7 Million
Q4 2019

Feb 14, 2020

SELL
$32.22 - $50.07 $8.06 Million - $12.5 Million
-250,000 Reduced 12.5%
1,750,000 $84.1 Million
Q3 2019

Nov 15, 2019

BUY
$33.82 - $48.17 $866,299 - $1.23 Million
25,615 Added 1.3%
2,000,000 $67.6 Million
Q2 2019

Aug 14, 2019

BUY
$35.42 - $45.0 $5.67 Million - $7.21 Million
160,125 Added 8.83%
1,974,385 $0
Q1 2019

May 14, 2019

BUY
$28.09 - $39.49 $16.6 Million - $23.3 Million
589,260 Added 48.1%
1,814,260 $68.3 Million
Q4 2018

Feb 15, 2019

BUY
$29.83 - $46.51 $15.1 Million - $23.6 Million
507,542 Added 70.74%
1,225,000 $42 Million
Q3 2018

Nov 14, 2018

SELL
$33.9 - $47.77 $28.9 Million - $40.7 Million
-851,042 Reduced 54.26%
717,458 $33.7 Million
Q2 2018

Aug 14, 2018

BUY
$25.7 - $47.88 $737,024 - $1.37 Million
28,678 Added 1.86%
1,568,500 $52.9 Million
Q1 2018

May 14, 2018

BUY
$17.46 - $32.59 $7.93 Million - $14.8 Million
454,022 Added 41.81%
1,539,822 $0
Q4 2017

Feb 14, 2018

SELL
$15.14 - $20.89 $214,988 - $296,638
-14,200 Reduced 1.29%
1,085,800 $18.1 Million
Q3 2017

Nov 14, 2017

BUY
$16.81 - $21.61 $18.5 Million - $23.8 Million
1,100,000
1,100,000 $22 Million

Others Institutions Holding PTCT

About PTC THERAPEUTICS, INC.


  • Ticker PTCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,541,000
  • Market Cap $3.31B
  • Description
  • PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...
More about PTCT
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.